Tandem Diabetes Care, Inc. (TNDM)
Tandem Diabetes Care, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $22.98, down 1.96% on the session, giving a market capitalisation of $1.57B. On trailing twelve-month figures it carries a trailing P/E of -24.74, a net margin of -6.1%. Its beta of 1.54 implies it has historically moved more than the broad market.
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Tandem Diabetes Care, Inc. is most often compared with the following Healthcare names: